FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968658169> ?p ?o ?g. }

• W1968658169 endingPage "S517" @default.
• W1968658169 startingPage "S517" @default.
• W1968658169 abstract "Purpose/Objective(s)Concurrent chemoradiation for patients (pts) with bulky SCLC or NSCLC can lead to a high risk of radiation pneumonitis (RP), which is correlated with the volume of irradiated normal lung. Induction chemotherapy (chemo) in such patients could lead to decreased tumor burden, thus smaller radiation fields and less radiation to normal lung. This study used virtual radiation therapy (RT) plans on the pre- and post- chemo CT scans of stage IV SCLC and NSCLC patients who received platin-based chemo alone, to measure the change in gross tumor volume (GTV), percent of lung receiving ≥ 20 Gy (V20), mean lung dose (MLD), and estimated risk of RP.Materials/MethodsAt the University of Colorado between 2003 and 2009, 23 pts with stage IV SCLC and 25 pts with stage IV NSCLC were treated with chemo alone (no surgery or RT) and had CT scans pre- and post- 2 cycles of platin-based chemo. Virtual RT plans were created as if to deliver 45 Gy and 66 Gy to the pre- and post-chemo thoracic disease in SCLC and NSCLC pts, respectively. Normal Tissue Complication Probability (NTCP) calculations were used to predict the pre- and post-chemo risk of pneumonitis ≥ Gr 2 based on simulated plans.ResultsEighteen of 23 (78%) SCLC pts had ≥ 30% reduction in GTV using volumetric measurements. The other 5 pts had stable disease. Among responders, mean decrease in GTV, V20, MLD and NTCP was 70% (range, 30-93%), 7.4% (range, -6.6 to 34%, p<0.01), 3.3 Gy (-0.13 to 12.1 Gy, p<0.01), and 5.5% (-0.1 to 28.5%, p<0.01), respectively. The mean relative reduction in GTV, V20, MLD, and NTCP was 70% (30 to 93%), 17% (-37 to 54%), 18% (-1 to 43%) and 28% (-1 to 65%), respectively. The absolute estimated risk of pneumonitis ≥ Gr 2 was decreased by ≥ 5% in 8 (35%) pts, while the relative risk was decreased by ≥30% in 8 (35%) pts. In total, there were 12 (52%) pts with either ≥ 5% absolute and/or ≥30% relative reduction in NTCP after induction chemo. Patients with bulky mediastinal lymphadenopathy and initial NTCP > 15% had a greater reduction in GTV and post-chemo NTCP (8.2% vs. 1.8%, p = 0.03) when compared to patients who had initial NTCP ≤ 15%. 8/25 (32%) NSCLC pts had ≥ 20% reduction in GTV (mean 44% [range 20 to 62%]) and 2/25 (8%) had > 25% progression, while 15 had stable disease. Pre- and post-chemo RT plans are pending.ConclusionsPatients with bulky limited SCLC will likely have a reduction in the risk of treatment related pneumonitis ≥ Gr 2 if treatment is planned following two cycles of induction chemotherapy. Patients with bulky mediastinal lymphadenopathy benefited more from induction chemotherapy with a significant reduction in estimated risk of RP. Induction chemo is less likely to significantly reduce risk of RP in NSCLC pts. Purpose/Objective(s)Concurrent chemoradiation for patients (pts) with bulky SCLC or NSCLC can lead to a high risk of radiation pneumonitis (RP), which is correlated with the volume of irradiated normal lung. Induction chemotherapy (chemo) in such patients could lead to decreased tumor burden, thus smaller radiation fields and less radiation to normal lung. This study used virtual radiation therapy (RT) plans on the pre- and post- chemo CT scans of stage IV SCLC and NSCLC patients who received platin-based chemo alone, to measure the change in gross tumor volume (GTV), percent of lung receiving ≥ 20 Gy (V20), mean lung dose (MLD), and estimated risk of RP. Concurrent chemoradiation for patients (pts) with bulky SCLC or NSCLC can lead to a high risk of radiation pneumonitis (RP), which is correlated with the volume of irradiated normal lung. Induction chemotherapy (chemo) in such patients could lead to decreased tumor burden, thus smaller radiation fields and less radiation to normal lung. This study used virtual radiation therapy (RT) plans on the pre- and post- chemo CT scans of stage IV SCLC and NSCLC patients who received platin-based chemo alone, to measure the change in gross tumor volume (GTV), percent of lung receiving ≥ 20 Gy (V20), mean lung dose (MLD), and estimated risk of RP. Materials/MethodsAt the University of Colorado between 2003 and 2009, 23 pts with stage IV SCLC and 25 pts with stage IV NSCLC were treated with chemo alone (no surgery or RT) and had CT scans pre- and post- 2 cycles of platin-based chemo. Virtual RT plans were created as if to deliver 45 Gy and 66 Gy to the pre- and post-chemo thoracic disease in SCLC and NSCLC pts, respectively. Normal Tissue Complication Probability (NTCP) calculations were used to predict the pre- and post-chemo risk of pneumonitis ≥ Gr 2 based on simulated plans. At the University of Colorado between 2003 and 2009, 23 pts with stage IV SCLC and 25 pts with stage IV NSCLC were treated with chemo alone (no surgery or RT) and had CT scans pre- and post- 2 cycles of platin-based chemo. Virtual RT plans were created as if to deliver 45 Gy and 66 Gy to the pre- and post-chemo thoracic disease in SCLC and NSCLC pts, respectively. Normal Tissue Complication Probability (NTCP) calculations were used to predict the pre- and post-chemo risk of pneumonitis ≥ Gr 2 based on simulated plans. ResultsEighteen of 23 (78%) SCLC pts had ≥ 30% reduction in GTV using volumetric measurements. The other 5 pts had stable disease. Among responders, mean decrease in GTV, V20, MLD and NTCP was 70% (range, 30-93%), 7.4% (range, -6.6 to 34%, p<0.01), 3.3 Gy (-0.13 to 12.1 Gy, p<0.01), and 5.5% (-0.1 to 28.5%, p<0.01), respectively. The mean relative reduction in GTV, V20, MLD, and NTCP was 70% (30 to 93%), 17% (-37 to 54%), 18% (-1 to 43%) and 28% (-1 to 65%), respectively. The absolute estimated risk of pneumonitis ≥ Gr 2 was decreased by ≥ 5% in 8 (35%) pts, while the relative risk was decreased by ≥30% in 8 (35%) pts. In total, there were 12 (52%) pts with either ≥ 5% absolute and/or ≥30% relative reduction in NTCP after induction chemo. Patients with bulky mediastinal lymphadenopathy and initial NTCP > 15% had a greater reduction in GTV and post-chemo NTCP (8.2% vs. 1.8%, p = 0.03) when compared to patients who had initial NTCP ≤ 15%. 8/25 (32%) NSCLC pts had ≥ 20% reduction in GTV (mean 44% [range 20 to 62%]) and 2/25 (8%) had > 25% progression, while 15 had stable disease. Pre- and post-chemo RT plans are pending. Eighteen of 23 (78%) SCLC pts had ≥ 30% reduction in GTV using volumetric measurements. The other 5 pts had stable disease. Among responders, mean decrease in GTV, V20, MLD and NTCP was 70% (range, 30-93%), 7.4% (range, -6.6 to 34%, p<0.01), 3.3 Gy (-0.13 to 12.1 Gy, p<0.01), and 5.5% (-0.1 to 28.5%, p<0.01), respectively. The mean relative reduction in GTV, V20, MLD, and NTCP was 70% (30 to 93%), 17% (-37 to 54%), 18% (-1 to 43%) and 28% (-1 to 65%), respectively. The absolute estimated risk of pneumonitis ≥ Gr 2 was decreased by ≥ 5% in 8 (35%) pts, while the relative risk was decreased by ≥30% in 8 (35%) pts. In total, there were 12 (52%) pts with either ≥ 5% absolute and/or ≥30% relative reduction in NTCP after induction chemo. Patients with bulky mediastinal lymphadenopathy and initial NTCP > 15% had a greater reduction in GTV and post-chemo NTCP (8.2% vs. 1.8%, p = 0.03) when compared to patients who had initial NTCP ≤ 15%. 8/25 (32%) NSCLC pts had ≥ 20% reduction in GTV (mean 44% [range 20 to 62%]) and 2/25 (8%) had > 25% progression, while 15 had stable disease. Pre- and post-chemo RT plans are pending. ConclusionsPatients with bulky limited SCLC will likely have a reduction in the risk of treatment related pneumonitis ≥ Gr 2 if treatment is planned following two cycles of induction chemotherapy. Patients with bulky mediastinal lymphadenopathy benefited more from induction chemotherapy with a significant reduction in estimated risk of RP. Induction chemo is less likely to significantly reduce risk of RP in NSCLC pts. Patients with bulky limited SCLC will likely have a reduction in the risk of treatment related pneumonitis ≥ Gr 2 if treatment is planned following two cycles of induction chemotherapy. Patients with bulky mediastinal lymphadenopathy benefited more from induction chemotherapy with a significant reduction in estimated risk of RP. Induction chemo is less likely to significantly reduce risk of RP in NSCLC pts." @default.
• W1968658169 created "2016-06-24" @default.
• W1968658169 creator A5012323508 @default.
• W1968658169 creator A5016271486 @default.
• W1968658169 creator A5052966036 @default.
• W1968658169 creator A5065231114 @default.
• W1968658169 creator A5067718653 @default.
• W1968658169 creator A5080301921 @default.
• W1968658169 creator A5082517668 @default.
• W1968658169 creator A5090235739 @default.
• W1968658169 date "2010-11-01" @default.
• W1968658169 modified "2023-09-26" @default.
• W1968658169 title "Impact of Induction Chemotherapy on Estimated Risk of Radiation Pneumonitis in Small Cell (SCLC) and Non-small Cell Lung (NSCLC) Cancer" @default.
• W1968658169 doi "https://doi.org/10.1016/j.ijrobp.2010.07.1206" @default.
• W1968658169 hasPublicationYear "2010" @default.
• W1968658169 type Work @default.
• W1968658169 sameAs 1968658169 @default.
• W1968658169 citedByCount "0" @default.
• W1968658169 crossrefType "journal-article" @default.
• W1968658169 hasAuthorship W1968658169A5012323508 @default.
• W1968658169 hasAuthorship W1968658169A5016271486 @default.
• W1968658169 hasAuthorship W1968658169A5052966036 @default.
• W1968658169 hasAuthorship W1968658169A5065231114 @default.
• W1968658169 hasAuthorship W1968658169A5067718653 @default.
• W1968658169 hasAuthorship W1968658169A5080301921 @default.
• W1968658169 hasAuthorship W1968658169A5082517668 @default.
• W1968658169 hasAuthorship W1968658169A5090235739 @default.
• W1968658169 hasConcept C126322002 @default.
• W1968658169 hasConcept C143998085 @default.
• W1968658169 hasConcept C2776256026 @default.
• W1968658169 hasConcept C2776611710 @default.
• W1968658169 hasConcept C2776694085 @default.
• W1968658169 hasConcept C2777714996 @default.
• W1968658169 hasConcept C2779292878 @default.
• W1968658169 hasConcept C2779524853 @default.
• W1968658169 hasConcept C2908954928 @default.
• W1968658169 hasConcept C2909444961 @default.
• W1968658169 hasConcept C509974204 @default.
• W1968658169 hasConcept C71924100 @default.
• W1968658169 hasConceptScore W1968658169C126322002 @default.
• W1968658169 hasConceptScore W1968658169C143998085 @default.
• W1968658169 hasConceptScore W1968658169C2776256026 @default.
• W1968658169 hasConceptScore W1968658169C2776611710 @default.
• W1968658169 hasConceptScore W1968658169C2776694085 @default.
• W1968658169 hasConceptScore W1968658169C2777714996 @default.
• W1968658169 hasConceptScore W1968658169C2779292878 @default.
• W1968658169 hasConceptScore W1968658169C2779524853 @default.
• W1968658169 hasConceptScore W1968658169C2908954928 @default.
• W1968658169 hasConceptScore W1968658169C2909444961 @default.
• W1968658169 hasConceptScore W1968658169C509974204 @default.
• W1968658169 hasConceptScore W1968658169C71924100 @default.
• W1968658169 hasIssue "3" @default.
• W1968658169 hasLocation W19686581691 @default.
• W1968658169 hasOpenAccess W1968658169 @default.
• W1968658169 hasPrimaryLocation W19686581691 @default.
• W1968658169 hasRelatedWork W1966706097 @default.
• W1968658169 hasRelatedWork W2057152092 @default.
• W1968658169 hasRelatedWork W2133367262 @default.
• W1968658169 hasRelatedWork W2397784636 @default.
• W1968658169 hasRelatedWork W2400080548 @default.
• W1968658169 hasRelatedWork W2407002657 @default.
• W1968658169 hasRelatedWork W2412189123 @default.
• W1968658169 hasRelatedWork W2999039869 @default.
• W1968658169 hasRelatedWork W3047601295 @default.
• W1968658169 hasRelatedWork W2119683243 @default.
• W1968658169 hasVolume "78" @default.
• W1968658169 isParatext "false" @default.
• W1968658169 isRetracted "false" @default.
• W1968658169 magId "1968658169" @default.
• W1968658169 workType "article" @default.